Health Care Equipment

Abbott Laboratories

NVision Completes $55 Million B Round Led by Abbott to Expand Quantum Computing Platform

Abbott Laboratories Sees Rising Dividend Yield Amid High Legal Costs and Infant Formula Litigation

Abbott Conducting Clinical Trial on BurstDR Technology for Diabetic Neuropathy Pain

Analysts Estimate and Rate Abbott Stock

Wells Fargo Analyst Reiterates Buy Rating on Abbott, Sets Price Target at $109

LAU Medical Center Successfully Conducts First Atrial Fibrillation Ablation Surgery

Multiple Executives Increase Stock Holdings

Abbott to Showcase New Clinical Evidence for Cancer Screening at DDW

Abbott Reports Q1 2026 Earnings: Revenue Exceeds Expectations, EPS Falls Short

Abbott Director Daniel J. Starks Buys Stocks and Receives Restricted Stock Units and Options

Abbott Launches Next-Generation Ultreon™ 3.0 AI-Driven Coronary Imaging Platform With FDA and CE Approvals

Abbott's CFO Philip Boudreau Purchased Company Shares

Abbott Showcases New Clinical Trial Data at 2026 Heart Rhythm Society

Leerink Partners expects to lower Abbott's target price to $106

UBS Analyst Reiterates Buy Rating on Abbott

Abbott to Present New Clinical Data for Cancerguard Multi-Cancer Early Detection Blood Test at AACR Annual Meeting

RBC Downgrades Abbott's Target Price to $130

Benchmark lowers Abbott's target price to $120

Mizuho lowers Abbott's target price to $115 from $125

Jefferies Downgrades Abbott's Target Price

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Abbott Laboratories (ABT.US) Q1 2026 Earnings Conference Call

Abbott Laboratories (ABT.US) Q4 2025 Earnings Conference Call

Abbott Laboratories (ABT.US) Q3 2025 Earnings Conference Call

Abbott Laboratories (ABT.US) Q2 2025 Earnings Conference Call

Abbott Laboratories (ABT.US) Q1 2025 Earnings Conference Call

Abbott Laboratories (ABT.US) Q4 2024 Earnings Conference Call

ISRG

CRWD

ServiceNow(NOW) rose 8.78%, with a trading turnover 5.2 Billion USD, and a year-to-date fell 32.5%. Accenture(ACN) rose 5.17%, with a trading turnover 940.2 Million USD, and a year-to-date fell 32.9%. Vertiv(VRT) fell 8.41%, with a trading turnover 2.7 Billion USD, and a year-to-date rose 109.7%. Corning(GLW) fell 6.91%, with a trading turnover 3.0 Billion USD, and a year-to-date rose 104.3%.

- The Nasdaq Composite Index fell by 0.51%, with a year-to-date gain of 12.3%.  
- The S&P 500 decreased by 0.07%, accumulating an 8.1% increase this year, while the Dow Jones rose by 0.32% with a 3.4% year-to-date gain.  
- Notable stock movements include NOW up 8.78% but down 32.5% year-to-date, while Accenture rose by 5.17% yet remains down 32.9% for the year, and Vertiv and Corning saw declines in daily trading but substantial yearly gains.

Top Gainers&Losers

ServiceNow

Accenture

Intuitive Surgical

CrowdStrike

Vertiv

Corning

Seagate Tech

Quanta Services

Micron Tech

Top 5 US Stock Gainers/Losers (>100B) (5.18)

ARKG

Cambridge Investment Research Advisors Inc. increased its holdings in Abbott Laboratories (NYSE:ABT) by 13.6% in Q4, owning 331,204 shares valued at $41.5 million. Other investors also raised their stakes. Insider transactions included Director Daniel J. Starks buying 10,000 shares and SVP Eric Shroff selling 709 shares. Analysts have adjusted price targets for Abbott, with an average target of $119.43 and a 'Moderate Buy' rating.

Market Beat

iShares US Pharma

iShares US Medical Devices

SPDR S&P Health Equip

Ark Genomic Revolution ETF

VG Health

iShares Global Healthcare

Health Care Select Sector SPDR

Abbvie

Oppenheimer

Barclays

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc.

EXAS

Abbott Laboratories recently completed a $21 billion acquisition of Exact Sciences, aiming to enhance its cancer diagnostics capabilities. Despite exceeding Q1 2026 sales and earnings expectations, Abbott faces significant legal challenges related to infant formula and securities litigation. The integration of Exact Sciences may lead to short-term earnings dilution, impacting investor sentiment. Analysts project Abbott's revenue could reach $59.7 billion by 2029, suggesting a potential 40% upside in stock value, but legal risks remain a concern for shareholders.

Simplywall

Exact Sciences

Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)

Abbott Laboratories (ABT) shares rose 1.28% to $84.90 on a strong trading day, outperforming competitors like Johnson & Johnson (JNJ) and Pfizer Inc. (PFE). The S&P 500 Index increased by 0.77%, while Abbott remains 38.95% below its 52-week high of $139.06. Trading volume was 10.9 million, below the 50-day average of 12.9 million. This information was generated by MarketWatch.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Pfizer

Merck

Abbott Laboratories Stock Outperforms Competitors On Strong Trading Day

ABBV

The article highlights three 'Strong Buy' Dividend Aristocrat stocks: AbbVie (ABBV), Abbott Laboratories (ABT), and NextEra Energy (NEE), all with payout ratios exceeding 100%. AbbVie has a payout ratio of 132.10% and a dividend yield of 3.23%, Abbott's is 140.52% with a yield of 2.89%, and NextEra's is 121.93% with a yield of 2.45%. Each stock is rated as a Strong Buy by analysts, indicating significant upside potential for investors seeking reliable dividend income.

Tip Ranks

Nextera Energy

Nextera Energy Partners LP

NEXTERA ENERGY CAPITAL HLDGS INC 5.65%JNR SUBORD DEB 01/03/2079 SER N

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 15/04/86 USD1000

NEXTERA ENERGY INC 6.926% CORPORATE UNITS 01/09/2025

NEXTERA ENERGY INC CORP UNIT 01/11/2029

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 01/06/85 USD25

NEXTERA ENERGY INC CORP UNIT 01/06/2027

NEXTERA ENERGY INC CORP UNIT

3 'Strong Buy' Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

Rayburn West Financial Services LLC acquired 16,587 shares of Abbott Laboratories (NYSE:ABT) during Q4, valued at approximately $2.08 million, making it the firm's 28th largest holding. Institutional investors own 75.18% of Abbott's stock. The company reported Q1 earnings of $1.15 per share, exceeding estimates, with revenue of $11.16 billion, up 7.8% year-over-year. Abbott also declared a quarterly dividend of $0.63 per share, yielding 3.0%. Analysts remain optimistic about Abbott's long-term growth despite recent post-earnings concerns.

Okta

Astellas Pharma

Astellas Pharma Inc.

Roche

ROCHE HOLDINGS AG

Rayburn West Financial Services LLC Buys Shares of 16,587 Abbott Laboratories $ABT

OKTA

Recent insider trading activity has been observed in Okta, Micron Technology, and Abbott Laboratories. Insiders are buying shares of Okta and Abbott, signaling confidence despite their stock declines. Okta's stock is down nearly 40% due to AI concerns, while Abbott has seen a 30% drop in 2026. Conversely, Micron's insiders have increased selling, with $45 million in sales, although most were under a 10b5-1 plan, indicating a lack of immediate concern. Overall, insider purchases in Abbott suggest potential recovery, while Micron's sales raise questions about future performance.

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

Abbott Laboratories(ABT.US)